+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Glomerulonephritis - Pipeline Drugs and Companies, Q2 2019

  • ID: 4762895
  • Report
  • April 2019
  • Region: Global
  • 150 pages
  • VPA Research
1 of 3


  • Algomedix Inc
  • ChemoCentryx Inc
  • Ergon Pharmaceuticals LLC
  • Merck KGaA
  • Oraxion Therapeutics Inc
  • Reata Pharmaceuticals Inc
  • MORE

Glomerulonephritis pipeline research report is a part of our 300+ Pharmaceutical and Healthcare disease pipeline report series. It provides detailed insights into Glomerulonephritis R&D activities including pipeline candidates, grants, developments, investments, technological advancements, and progress.

Extensive Coverage of Pipeline Candidates

The Glomerulonephritis report covers all the pre-clinical compounds and clinical compounds under evaluation for treatment of Glomerulonephritis as of 2019. All preclinical, research, discovery, pre registration, phase 1, phase 2, and phase 3 trials active are included in the study.

Over 10 descriptive details provided for each Pipeline Product

Complete analysis of therapeutics for treatment of Glomerulonephritis with details of current status of development, pipeline phase, drug target, mechanism of action (MoA), route of administration (RoA), participating companies, originator, collaborators and molecule type are included. The study also covers the historic developments, pharmacological action and recent developments associated with each drug.

Companies participating in Glomerulonephritis pipeline Profiled in detail

Key players actively participating in Glomerulonephritis pipeline are profiled along with their R&D progress in Glomerulonephritis treatment are provided. Companies /Universities /Institutes participating as originators, collaborators, licensors, investors, and marketing or developing companies are detailed in the report. Further, for all the developing companies, detailed profile is also provided.

Information Sourced from in-house Proprietary Databases

The report is developed using information from in-house database developed over years through daily updates from company reports, websites, events, conferences, news, announcements, clinical trial registries, regulatory authorities, universities and industry associations.

Report assists users in taking actionable steps

Glomerulonephritis pipeline report enables users to gain clear understanding into large and small companies participating in the pipeline and detailed insights into their product portfolio. The guide presents also available opportunities for new business in Glomerulonephritis treatment pipeline.

The report includes:
  • The research work provides comprehensive overview of Glomerulonephritis pipeline and treatment landscape
  • Complete list of drug candidates from discovery to pre-registration phases are analyzed
  • Companies and universities participating in the pipeline are analyzed in detail along with their drug development product portfolio
  • Detailed drug profiles of Glomerulonephritis pipeline compounds including status, phase, mechanism of action, route of administration, originators, licensing and collaborating companies, grants, technological advancements and investments are detailed
  • Research and Development progress and trial details, results wherever available, are also included in the Glomerulonephritis pipeline study
  • All recent news and developments related to Glomerulonephritis drugs are provided
Note: Product cover images may vary from those shown
2 of 3


  • Algomedix Inc
  • ChemoCentryx Inc
  • Ergon Pharmaceuticals LLC
  • Merck KGaA
  • Oraxion Therapeutics Inc
  • Reata Pharmaceuticals Inc
  • MORE
1. Introduction
1.1. Pipeline Snapshot, 2019
1.2. Overview Pipeline Activities in 2019

2. Glomerulonephritis Disease Overview

3. Glomerulonephritis R&D Pipeline Trends
3.1. Pipeline Drugs under development by phase, 2019
3.2. Pipeline Drugs by Mechanism of Action, 2019
3.3. Pipeline Drugs by Route of Administration, 2019
3.4. Pipeline Drugs by Company, 2019
3.5. Pipeline Drugs by Molecule Type, 2019

4. Glomerulonephritis Pre-clinical and Discovery Phase Drug Profiles
4.1. Drug Name/Alternative Names
4.2. Originator
4.3. Licensor/Developer/Collaborators
4.4. Class
4.5. Mechanism of Action
4.6. Route of Administration
4.7. Orphan Drug Status
4.8. New Molecular Entity
4.9. Current Status
4.10. Trial Landscape
4.11. Development History

5. Glomerulonephritis Clinical Phase Drug Profiles
5.1. Drug Name/Alternative Names
5.2. Originator
5.3. Licensor/Developer/Collaborators
5.4. Class
5.5. Mechanism of Action
5.6. Route of Administration
5.7. Orphan Drug Status
5.8. New Molecular Entity
5.9. Current Status
5.10. Trial Landscape
5.11. Development History

6. Company Profiles
6.1. Glomerulonephritis companies
6.1.1. Business Profile
6.1.2. Pipeline Products
6.1.3. Glomerulonephritis Activities

7. Recent News Landscape

8. Appendix
8.1. Sources and Research Methodology
8.2. Publisher Expertise
8.3. Database and Custom Services
Note: Product cover images may vary from those shown
3 of 3


4 of 3
  • Achillion Pharmaceuticals Inc
  • Alexion Pharmaceuticals Inc
  • Algomedix Inc
  • Amyndas Pharmaceuticals LLC
  • Apellis Pharmaceuticals Inc
  • Avexxin AS
  • Biogen Inc
  • Calliditas Therapeutics AB
  • ChemoCentryx Inc
  • Complexa Inc
  • Cytodesign Inc
  • Dimerix Bioscience Pty Ltd
  • Ergon Pharmaceuticals LLC
  • Goldfinch Biopharma Inc
  • Kyowa Hakko Kirin Co Ltd
  • Merck KGaA
  • Novartis AG
  • Omeros Corporation
  • Oraxion Therapeutics Inc
  • Pfizer Inc
  • Polyneuron Pharmaceuticals AG
  • Ra Pharmaceuticals Inc
  • Reata Pharmaceuticals Inc
  • Retrophin Inc
  • Rigel Pharmaceuticals Inc
  • Sarfez Pharmaceuticals Inc
  • Shire Plc
  • Sujana Biotech LLC
  • Variant Pharmaceuticals Inc
  • Visterra Inc
Note: Product cover images may vary from those shown